Post by Brian Roebuck on Dec 21, 2007 16:28:33 GMT -5
Lundbeck plans new trial with bat drug
Fri Dec 21, 2007 8:47am EST
COPENHAGEN, Dec 21 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: Quote, Profile, Research) said on Friday it planned a new Phase III trial with partner Paion's (PA8G.DE: Quote, Profile, Research) drug desmoteplase, based on bat saliva, to treat acute ischaemic stroke.
The two companies also entered into a new agreement that gives Lundbeck global exclusive rights to the drug, including North America, with Paion retaining an option to co-promote it in Germany, Switzerland and Austria.
The experimental drug is based on the ability of bat saliva to prevent the blood of its prey from clotting as the bat feeds. It failed in a previous major study, but Paion said that study was flawed as a high percentage of the patients enrolled did not have a blood clot in the main brain arteries for desmoteplase to dissolve.
www.reuters.com/article/rbssHealthcareNews/idUSL2130320720071221
Fri Dec 21, 2007 8:47am EST
COPENHAGEN, Dec 21 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: Quote, Profile, Research) said on Friday it planned a new Phase III trial with partner Paion's (PA8G.DE: Quote, Profile, Research) drug desmoteplase, based on bat saliva, to treat acute ischaemic stroke.
The two companies also entered into a new agreement that gives Lundbeck global exclusive rights to the drug, including North America, with Paion retaining an option to co-promote it in Germany, Switzerland and Austria.
The experimental drug is based on the ability of bat saliva to prevent the blood of its prey from clotting as the bat feeds. It failed in a previous major study, but Paion said that study was flawed as a high percentage of the patients enrolled did not have a blood clot in the main brain arteries for desmoteplase to dissolve.
www.reuters.com/article/rbssHealthcareNews/idUSL2130320720071221